671 related articles for article (PubMed ID: 37006306)
1. Targeting myeloid-derived suppressor cells in tumor immunotherapy: Current, future and beyond.
Zhao Y; Du J; Shen X
Front Immunol; 2023; 14():1157537. PubMed ID: 37006306
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy Targeting Myeloid-Derived Suppressor Cells (MDSCs) in Tumor Microenvironment.
Gao X; Sui H; Zhao S; Gao X; Su Y; Qu P
Front Immunol; 2020; 11():585214. PubMed ID: 33613512
[TBL] [Abstract][Full Text] [Related]
3. Targeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy.
Joshi S; Sharabi A
Pharmacol Ther; 2022 Jul; 235():108114. PubMed ID: 35122833
[TBL] [Abstract][Full Text] [Related]
4. Myeloid-Derived Suppressor Cells in the Tumor Microenvironment.
Dysthe M; Parihar R
Adv Exp Med Biol; 2020; 1224():117-140. PubMed ID: 32036608
[TBL] [Abstract][Full Text] [Related]
5. Natural Killer Cell Interactions With Myeloid Derived Suppressor Cells in the Tumor Microenvironment and Implications for Cancer Immunotherapy.
Zalfa C; Paust S
Front Immunol; 2021; 12():633205. PubMed ID: 34025641
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy of targeting MDSCs in tumor microenvironment.
Sui H; Dongye S; Liu X; Xu X; Wang L; Jin CQ; Yao M; Gong Z; Jiang D; Zhang K; Liu Y; Liu H; Jiang G; Su Y
Front Immunol; 2022; 13():990463. PubMed ID: 36131911
[TBL] [Abstract][Full Text] [Related]
7. Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression.
Fleming V; Hu X; Weber R; Nagibin V; Groth C; Altevogt P; Utikal J; Umansky V
Front Immunol; 2018; 9():398. PubMed ID: 29552012
[TBL] [Abstract][Full Text] [Related]
8. Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression.
Groth C; Hu X; Weber R; Fleming V; Altevogt P; Utikal J; Umansky V
Br J Cancer; 2019 Jan; 120(1):16-25. PubMed ID: 30413826
[TBL] [Abstract][Full Text] [Related]
9. The New Era of Cancer Immunotherapy: Targeting Myeloid-Derived Suppressor Cells to Overcome Immune Evasion.
De Cicco P; Ercolano G; Ianaro A
Front Immunol; 2020; 11():1680. PubMed ID: 32849585
[TBL] [Abstract][Full Text] [Related]
10. Tumor microenvironment, histone modifications, and myeloid-derived suppressor cells.
Tian X; Wang T; Shen H; Wang S
Cytokine Growth Factor Rev; 2023 Dec; 74():108-121. PubMed ID: 37598011
[TBL] [Abstract][Full Text] [Related]
11. Myeloid-Derived Suppressor Cells in Prostate Cancer: Present Knowledge and Future Perspectives.
Koinis F; Xagara A; Chantzara E; Leontopoulou V; Aidarinis C; Kotsakis A
Cells; 2021 Dec; 11(1):. PubMed ID: 35011582
[TBL] [Abstract][Full Text] [Related]
12. Myeloid-derived suppressor cells: Key immunosuppressive regulators and therapeutic targets in cancer.
Li L; Li M; Jia Q
Pathol Res Pract; 2023 Aug; 248():154711. PubMed ID: 37494802
[TBL] [Abstract][Full Text] [Related]
13. New Insights into the Multifaceted Role of Myeloid-Derived Suppressor Cells (MDSCs) in High-Grade Gliomas: From Metabolic Reprograming, Immunosuppression, and Therapeutic Resistance to Current Strategies for Targeting MDSCs.
Lakshmanachetty S; Cruz-Cruz J; Hoffmeyer E; Cole AP; Mitra SS
Cells; 2021 Apr; 10(4):. PubMed ID: 33919732
[TBL] [Abstract][Full Text] [Related]
14. Nanoparticle Systems Modulating Myeloid-Derived Suppressor Cells for Cancer Immunotherapy.
Wilkerson A; Kim J; Huang AY; Zhang M
Curr Top Med Chem; 2017; 17(16):1843-1857. PubMed ID: 27875974
[TBL] [Abstract][Full Text] [Related]
15. Modulation of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment by Natural Products.
Calderon JJ; Prieto K; Lasso P; Fiorentino S; Barreto A
Arch Immunol Ther Exp (Warsz); 2023 Jul; 71(1):17. PubMed ID: 37410164
[TBL] [Abstract][Full Text] [Related]
16. A Complex Metabolic Network Confers Immunosuppressive Functions to Myeloid-Derived Suppressor Cells (MDSCs) within the Tumour Microenvironment.
Hofer F; Di Sario G; Musiu C; Sartoris S; De Sanctis F; Ugel S
Cells; 2021 Oct; 10(10):. PubMed ID: 34685679
[TBL] [Abstract][Full Text] [Related]
17. Visualization and quantification of
Hoffmann SHL; Reck DI; Maurer A; Fehrenbacher B; Sceneay JE; Poxleitner M; Öz HH; Ehrlichmann W; Reischl G; Fuchs K; Schaller M; Hartl D; Kneilling M; Möller A; Pichler BJ; Griessinger CM
Theranostics; 2019; 9(20):5869-5885. PubMed ID: 31534525
[TBL] [Abstract][Full Text] [Related]
18. Cancer-cell-intrinsic mechanisms regulate MDSCs through cytokine networks.
Zhang Y; Murphy S; Lu X
Int Rev Cell Mol Biol; 2023; 375():1-31. PubMed ID: 36967150
[TBL] [Abstract][Full Text] [Related]
19. Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy.
Wu Y; Yi M; Niu M; Mei Q; Wu K
Mol Cancer; 2022 Sep; 21(1):184. PubMed ID: 36163047
[TBL] [Abstract][Full Text] [Related]
20. Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer.
Li K; Shi H; Zhang B; Ou X; Ma Q; Chen Y; Shu P; Li D; Wang Y
Signal Transduct Target Ther; 2021 Oct; 6(1):362. PubMed ID: 34620838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
